A1C CONTROL

It dramatically reduces blood glucose and weight by combining a glucagon-like peptide-1 receptor agonist (GLP-1 RA) with a glucose-dependent insulinotropic polypeptide (GIP). The therapy brought significantly greater reductions in glycated hemoglobin (A1C) and weight than semaglutide, a well-known GLP-1 RA. Many patients whose A1C is above 8% never achieve glycemic control, which can lead to multiple long-term complications, including blindness or cardiovascular events.

GLP-1 RA tirzepatide offers an option that could reduce A1C and help patients lose weight, but even this powerful incretin needed a helper. Enter GIP, which further aids—and optimizes—the right amount of insulin secretion.

WEIGHT LOSS

Even though Tirzepatide has been approved for type 2 diabetes, studies indicate that it could be the most effective weight loss drug ever produced. Tirzepatide has three main mechanisms of action. It enhances the growth of beta cells in the pancreas, which are sites of insulin production. This means your body has improved control over blood sugar spikes. Compounded tirzepatide also delays gastric emptying. The delay in gastric emptying can reduce appetite. Finally, tirzepatide improves control of eating and reduces food cravings.